Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kaisa Health Group Holdings's quarterly market cap
declined
from Dec. 2024 (HK$121.0 Mil) to Jun. 2025 (HK$95.8 Mil) but then
increased
from Jun. 2025 (HK$95.8 Mil) to Dec. 2025 (HK$353.0 Mil).
Kaisa Health Group Holdings's annual market cap
declined
from Dec. 2023 (HK$171.4 Mil) to Dec. 2024 (HK$121.0 Mil) but then
increased
from Dec. 2024 (HK$121.0 Mil) to Dec. 2025 (HK$353.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Kaisa Health Group Holdings's Enterprise Value for Today is HK$106.2 Mil.
Kaisa Health Group Holdings (HKSE:00876) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Kaisa Health Group Holdings Market Cap Related Terms
Kaisa Health Group Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:00876 vs ISRG, BDX, MDLN: Market Cap Comparison
For the Medical Instruments & Supplies subindustry, Kaisa Health Group Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaisa Health Group Holdings Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kaisa Health Group Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Kaisa Health Group Holdings's Market Cap falls into.
Kaisa Health Group Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaisa Health Group Holdings (HKSE:00876) has a Market Cap of HK$295.9 Mil as of Aug. 11, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kaisa Health Group Holdings and its competitors. According to the industry distribution chart, Kaisa Health Group Holdings ranks #583 out of 861 companies in the Medical Devices & Instruments industry, placing it in the top 67.7%.
Is Kaisa Health Group Holdings' Market Cap too high?
Kaisa Health Group Holdings' current Market Cap is HK$295.9 Mil. Based on the distribution chart, Kaisa Health Group Holdings ranks #583 out of 861 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Kaisa Health Group Holdings has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kaisa Health Group Holdings' Market Cap compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Kaisa Health Group Holdings ranks #583 out of 861 companies for Market Cap. This places Kaisa Health Group Holdings in the lower half of its industry. The industry median Market Cap is 119.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 119.77, based on 861 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kaisa Health Group Holdings and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 119.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaisa Health Group Holdings's current Market Cap is HK$295.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaisa Health Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Kaisa Health Group Holdings (HKSE:00876) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.95, compared to a current price of HK$2.86 — trading 200.5% above its estimated fair value. The current Market Cap is HK$295.9 Mil. Kaisa Health Group Holdings' overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Kaisa Health Group Holdings (HKSE:00876), the current Market Cap is HK$295.9 Mil as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaisa Health Group Holdings (HKSE:00876) Overvalued in 2026?
Based on GuruFocus' analysis, Kaisa Health Group Holdings stock appears to be overvalued.
The current stock price of HK$2.86 is trading 200.5% above its estimated GF Value™ of HK$0.95.
GuruFocus considers Kaisa Health Group Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:00876:
Market Cap: HK$295.9 Mil
GF Value™: HK$0.95 vs. price of HK$2.86 (200.5% above fair value)
No single metric tells the full story. See the HKSE:00876 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaisa Health Group Holdings Ltd, through its subsidiaries are mainly engaged in the manufacturing and sale of dental prosthetics and implant instruments, and the provision of sports rehabilitation services. The Group operates in two reportable segments: Dental Business, which consists of manufacturing and trading in dental products; and the Health Care Business, which provides services for sport rehabilitation, including postoperative rehabilitation, sports injury rehabilitation, chronic pain, scoliosis, deformity correction, other rehabilitation services, and health leisure business. The majority of its revenue is generated from the Dental business segment. Geographically, the Group generates maximum revenue from the People's Republic of China, and the rest from other countries.
40GF Score
Get the complete analysis for HKSE:00876
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00876 has been successfully added to your 
